logo
logo
ANIK stock ticker logo

Anika Therapeutics, Inc.

NASDAQ•ANIK
CEO: Dr. Cheryl Renee Blanchard Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1993-05-03
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Contact Information
32 Wiggins Avenue, Bedford, MA, 01730, United States
781-457-9000
www.anika.com
Market Cap
$206.22M
P/E (TTM)
-18.8
27
Dividend Yield
--
52W High
$17.10
52W Low
$7.87
52W Range
70%
Rank31Top 21.6%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$30.62M+0.00%
4-Quarter Trend

EPS

$0.02+0.00%
4-Quarter Trend

FCF

$3.99M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Reduction Net loss 10.9M USD, improved 81% from 56.4M USD in 2024, reflecting successful divestitures and operational cost management.
Commercial Channel Growth Commercial revenue 48.4M USD, up 15%, driven by international sales growth and strong adoption of Integrity Implant System.
Cash Position Stability Cash and equivalents 57.5M USD, up from 55.6M USD in 2024, supporting ongoing R&D and strategic growth initiatives.

Risk Factors

Customer Concentration Risk J&J MedTech accounted for 50% of 2025 revenue; loss or reduced orders from this key partner would harm operations.
Regulatory Approval Delays Hyalofast PMA received deficiency letter in Jan 2026; delays in FDA clearance for Cingal and Hyalofast impact future revenue.
Manufacturing Dependency Risks Global supply relies on single Bedford facility; disruption or failure to meet quality standards could materially impact financial results.

Outlook

Integrity System Expansion Focus on commercial execution and adoption of Integrity Implant System to drive growth in the 220M USD tendon augmentation market.
Pipeline R&D Investment Committing resources to Hyalofast and Cingal regulatory pathways, targeting U.S. addressable markets of at least 1B USD each.
Operational Efficiency Focus Investing in Bedford manufacturing facility to enhance capabilities and meet growing demand for innovative orthopedic and regenerative solutions.

Peer Comparison

Revenue (TTM)

ARAY stock ticker logoARAY
$436.97M
-3.6%
DCGO stock ticker logoDCGO
$368.09M
-47.0%
QIPT stock ticker logoQIPT
$285.31M
+19.3%

Gross Margin (Latest Quarter)

QIPT stock ticker logoQIPT
97.9%
+104.6pp
MXCT stock ticker logoMXCT
92.4%
+16.1pp
RCEL stock ticker logoRCEL
81.2%
-2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANIK$206.22M-18.8-7.4%12.7%
QIPT$162.30M-14.3-9.9%41.2%
RPID$151.80M-3.2-95.4%31.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.4%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Deep Research

Next earnings:May 7, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data